Human Papillomavirus in Young People Epidemiological Research 4

Last updated: March 13, 2023
Sponsor: Monash University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Anal Dysplasia

Cancer

Human Papilloma Virus (Hpv)

Treatment

N/A

Clinical Study ID

NCT05587738
15/22
  • Ages 21-25
  • Male

Study Summary

Anal cancer is overrepresented among gay, bisexual and other men who have sex with men (MSM), particularly those living with HIV. Australia was the first country to introduce a publicly funded national HPV vaccination program in 2007. This program was expanded to include schoolboys aged 12-13 years in 2013; with a 2-year catch-up for boys aged up to 15 years.

The goal of the HYPER4 study is to determine the prevalence of anal, genital and oral HPV among 500 young gay and bisexual men aged 21-25 years who were eligible for the school-based gender-neutral quadrivalent vaccination program.

Participants will be required to complete a questionnaire and provide samples for HPV testing. No follow-up visits will be required.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Men aged 21 to 25 years old in 2023-2024
  • Same-sex attracted
  • Residing in Australia since 2013

Exclusion

Exclusion Criteria:

  • Unable to complete all study requirements in English

Study Design

Total Participants: 500
Study Start date:
January 01, 2023
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • Melbourne Sexual Health Centre

    Melbourne, Victoria 3053
    Australia

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.